Schematic representation of the study approach. Verification group1: Eighty-nine genes were selected for gene expression analysis using TaqMan Low Density Array, TLDA, see text for details. In the TLDA analysis, six favourable (F) and six unfavourable (UF) tumours were included. Verification group 2: Twelve candidate genes were selected for validation by TaqMan individual QPCR, TM (see Table 3 for selection criteria). A new, randomly selected set of favourable (n = 7) and unfavourable (n= 6) tumours were used in the analyses, and all samples were run in duplicates (×2).
Thorell et al. BMC Medical Genomics 2009 2:53 doi:10.1186/1755-8794-2-53